Development of an epitope-based vaccination strategy designed to enhance Epstein-Barr virus (EBV)-specific CD8 + cytotoxic T lymphocytes is increasingly being considered as a preferred approach for the treatment of EBV-associated relapsed 
Introduction
The concept of a role for the immune system in the control and elimination of virus-infected malignant cells has existed for many years, giving rise to the theory of immunological surveillance against tumours. More recently, it has been established that tumour rejection is mediated by lymphocytes and most notably by cytotoxic T lymphocytes (CTL). This concept is based mainly on the assumption that, like normal In spite of the highly immunogenic phenotypes associated with these malignancies, tumour cells in NPC and HD can escape CTL-mediated immune control in vivo. A number of possible mechanisms have been proposed to explain this immune evasion strategy. Immunological and biochemical analysis of LMP1 sequences associated with NPC and HD have shown that these sequences are not only highly oncogenic but seem to be poorly immunogenic in murine models when compared with the LMP1 sequences derived from normal EBV-infected B cells 5; 6 . Moreover, independent studies by different groups have also shown that Reed-Sternberg cells in HD secrete anti-inflammatory cytokines (such as IL10 and TGFß), which may interfere with the activation of LMP-specific CTLs 7 .
For personal use only. on October 17, 2017 . by guest www.bloodjournal.org From It has been proposed that strategies designed to augment LMP1-and/or LMP2-specific CTL responses in HD and NPC patients may provide a therapeutic benefit for these malignancies. Indeed, adoptive transfer of polyclonal EBV-specific autologous CTLs into patients with advanced HD has recently been reported 8 . In this study, all patients who received this adoptive therapy had incidental improvement, including reduction of high virus load, increase in virus-specific CTL precursor frequency, resolution of some symptoms and stabilization of the disease. Unfortunately, all of these patients failed to recover from the advanced stages of HD. One of the major limitations of this approach was that the CTLs transferred in this study were expanded by stimulating the peripheral blood lymphocytes with autologous EBV transformed lymphoblastoid cell lines (LCLs) which are known to preferentially stimulate T cells specific for EBNA antigens rather than LMP1 and LMP2. In spite of these limitations, it was encouraging to see a short-term therapeutic effect and further improvement of the CTL activation strategy may allow selective expansion of T cells that are specific for a limited range of viral antigens expressed in HD and NPC. In the present study, we have developed a novel strategy based on an LMP1 polyepitope vaccine, which allows an efficient activation of LMP1-specific CTL responses in vivo and these CTLs in turn provide a strong therapeutic benefit against LMP1-expressing tumours.
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Materials and Methods

Construction of a Recombinant LMP Polyepitope Expression Vector
The amino acid sequences of six contiguous minimal LMP1 CTL epitopes 
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These cell lines were routinely maintained in RPMI 1640 (Gibco Invitrogen Corp., Carlsbad, CA) supplemented with 2 mM L-glutamine, 100 IU/ml penicillin and 100 µg/ml streptomycin plus 10% FCS (growth medium). In addition, a mouse thymoma tumour cell line EL4 expressing a HLA A2/K b chimeric molecule (referred to as EL4-A2/ K b ) was also used in this study. These cells were maintained in growth medium supplemented with G418 (500ug/ml). EL4-A2/ K b cells were transfected with an expression vector encoding full-length genomic B95.8 LMP1 (pSG5-LMP1; referred to as EL4-A2/ K b -LMP1) and cultured in growth medium supplemented with G418
(500ug/ml) for 4-6 weeks. Expression of LMP1 protein in EL4-A2/ K b -LMP1 cells was confirmed by immunofluorescence and western blotting using an LMP1-specific CS1-4
antibody (Dako, Botany, Australia). For personal use only. on October 17, 2017 . by guest www.bloodjournal.org From remaining CTL cultures were restimulated as described above on day 6 and tested for CTL activity again on day 10.
Synthesis of Peptides
Peptides, synthesized by the Merrifield solid phase method, were purchased from Chiron Mimotopes (Melbourne, Australia), dissolved in dimethyl sulphoxide, and diluted in serum-free RPMI 1640 medium for use in standard CTL assays. Purity of these peptides were tested by mass spectrometery and showed >90% purity.
Assessment of T cell Responses by IFN-γ ELISPOT Assay
This assay is based on a modification of the IFN-γ ELISPOT method described previously 13; 14 . Ninety six-well mixed cellulose ester membrane plates (Millipore, Bedford, USA) were coated overnight at 4°C with 75µL/well of 8µg/ml anti-IFN-γ, capture mAb (PharMingen, clone R4-6A2) in freshly prepared filter-sterilized 0.1M 
Establishment of Human Polyclonal CTL Lines and LMP1-Specific CTL Clones
Polyclonal CTL lines and LMP1-specific CTL clones were established according to previously published methods Cr-release assays.
In vivo cytotoxicity assays
LMP1 epitope-specific in vivo CTL activity was assessed by using CFSE dye (Table 1) was derived using homologous recombination. To test whether the LMP1 epitopes encoded by this polyepitope were endogenously processed, target cells infected with Vacc.polyLMP were exposed to LMP1-specific CTL polyclonal/clonal lines specific for YLLEMLWRL (referred to as YLL) and YLQQNWWTL (referred to as YLQ) epitopes. These CTL lines were generated from healthy virus carriers and their specificity was confirmed by their ability to lyse HLA A2-positive target cells coated with respective peptide epitopes ( Fig. 2; panel A). HLA A2-positive fibroblast infected with Vacc.polyLMP were also efficiently recognized by YLL-and YLQ-specific CTL lines ( Fig. 2; show that all mice consistently responded to five (YLL, YLQ, TLL, LLV and LLL) of the six LMP1 CTL epitopes included in the polyepitope vaccine. On the other hand, low levels of T cell response to RLG epitope were detected (Fig. 3) .
In the next set of experiments, these precursor T cells were stimulated in vitro to determine whether epitope specific CTL effectors could be expanded following immunization with the LMP polyepitope. Representative data from a group of six animals is shown in figure 4 . Following a single stimulation with peptide sensitized LPS blasts, strong CTL responses to two epitopes (YLL and TLL) were detected, while a low to moderate response to the LLV epitope was detected. No epitope-specific lysis was detected for LLL and YLQ epitopes. However, a significant increase in the levels of CTL lysis was observed following secondary stimulation with peptidesensitized LPS blasts. It is important to mention here that no CTL effectors were expanded following stimulation with the RLG peptide. These observations are consistent with our ELISPOT data presented in figure 3 . 
Comparative Analysis of T cell Responses to LMP1 Epitopes in HLA A2/Kb Mice
Following Tumour Challenge
To determine whether the CTL responses in vivo correlated with the tumour protection, LMP1-specific T cell responses were assessed following tumour challenge.
Data from one such analysis is presented in figure 8 . All animals immunized with Vacc.polyLMP vaccine and showing complete protection from tumour challenge demonstrated strong ex vivo LMP1 epitope-specific CTL responses. One of the interesting aspects of this result was that a significant increase in the T cell response to the RLGATIWQL epitope was observed following tumour challenge. Our initial studies (see figure 3 ) had indicated that very low levels of CTL responses are generated to RLGATIWQL epitope following immunization with Vacc.polyLMP vaccine.
Furthermore, the levels of T cell responses to the LMP1 epitopes in individual mice showed strong correlation with the tumour load on day 21. Those mice with higher precursor frequency for LMP1 epitopes showed complete resolution of tumour, while small tumours were evident in those mice which had lower precursor frequency. These observations clearly indicate that a strong T cell response to LMP1 is crucial for a successful rejection of the LMP-expressing tumours. This contention is further 
Discussion
Over the past several decades, the goal of curing the majority of patients with primary HD and NPC has been reached. In the past three decades, two powerful tools, irradiation and multi-agent chemotherapy have emerged as the mainstays of modern treatment (reviewed in 17). Although both these therapeutic strategies are most efficient in eradicating a proportion of tumors, the non-specific nature of these treatments often results in significant side effects including long-term toxicites, development of secondary cancers and infectious complications 18 . Moreover, a small but significant proportion of HD and NPC patients relapse following chemo-and radiotherapy and also fail to respond to conventional therapeutic salvage strategies. More recently, there has been an increasing emphasis on the development of novel therapeutic strategies which are specifically designed to prime the patient's own immune system to recognise EBV antigens expressed in malignant cells of HD and NPC and to specifically destroy these cells with minimal or no associated toxicities 19, 20 .
The present study illustrates the possibility of using multiple HLA class I- 
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The data presented here provide an important platform for the future development of immunotherapeutic strategies for the treatment of EBV-associated relapsed HD and NPC. Although HLA A2 is one of most common HLA class I alleles, the wider application of LMP-based polyepitope technology will require the inclusion of CTL epitopes restricted through other HLA class I alleles prevalent in NPC endemic regions of the world (HLA A11, A24, B27 and B57). Moreover, inclusion of additional epitopes from LMP1 and LMP2 will also allow the targeting of both antigens. We anticipate that the translation of polyepitope vaccine technology for human application will require other delivery modalities which are more likely to be approved by safety and human ethics committees. These include replication deficient adenovirus, poxvirus (Modified Vaccinia Ankara) vectors, naked DNA, or transduced autologous dendritic cells [21] [22] [23] . Considering the highly immunosuppressive nature of malignant cells of HD, it is possible that LMP1 and LMP2 CTL induction might need to be facilitated by codelivery of cytokines and/or prime boost strategies 24 . Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society
